Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma

22 Nov 2019

Abstract excerpt

A mutation in the isocitrate dehydrogenase 1 (IDH1) gene is the most common mutation in diffuse lower-grade gliomas (LGGs), and it is significantly related to the prognosis of LGGs. We aimed to explore the influence of the IDH1 mutation on the immune microenvironment and develop an IDH1-associated immune prognostic signature (IPS) for predicting prognosis in LGGs. IDH1 mutation status and RNA expression were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis
Share to Glioma Diagnosis and Treatment
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31824866
DOI: 10.3389/fonc.2019.01310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaPMID 31824866Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade GliomasSemantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

Classification of diffuse lower‐grade glioma based on immunological profilingSemantic proximity Read ↗

Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.Semantic proximity Read ↗

Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade gliomaSemantic proximity Read ↗

A gene signature predicting prognosis of patients with low- grade gliomas receiving temozolomide therapySemantic proximity Read ↗

Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade GliomaSemantic proximity Read ↗

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.Semantic proximity Read ↗

A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.Semantic proximity Read ↗

Leveraging a diverse cell-death patterns-based signature to predict the prognosis of low- grade gliomasSemantic proximity Read ↗

The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse GliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.